SYNAGEVA BIOPHARMA CORP 4

Accession 0001209191-15-051540

CIK 0000911326operating

View on SEC.gov Company Profile

Filed

Jun 8, 8:00 PM ET

Accepted

Jun 9, 6:13 PM ET

Size

20.8 KB

Accession

0001209191-15-051540

Insider Transaction Report

Form 4

Period: 2015-06-05

SYNAGEVA BIOPHARMA CORPGEVA

Williams Glen

SVP, Technical Operations

Transactions

Sale
Common Stock
2015-06-08$215.72/sh−2,520$543,614→ 25,968 total
Exercise/Conversion
Common Stock
2015-06-08$40.32/sh+833$33,587→ 26,801 total
Exercise/Conversion
Common Stock
2015-06-08$80.35/sh+11,250$903,937→ 38,884 total
Exercise/Conversion
Stock Option (Right to Buy)
2015-06-08−11,250→ 33,750 total
Exercise: $80.35Exp: 2024-06-04→ Common Stock (11,250 underlying)
Award
Common Stock
2015-06-05+25,500→ 25,968 total
Exercise/Conversion
Common Stock
2015-06-08$57.56/sh+833$47,947→ 27,634 total
Sale
Common Stock
2015-06-08$214.72/sh−10,396$2,232,229→ 28,488 total
Exercise/Conversion
Stock Option (Right to Buy)
2015-06-08−833→ 20,002 total
Exercise: $40.32Exp: 2023-06-06→ Common Stock (833 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2015-06-08−833→ 13,334 total
Exercise: $57.56Exp: 2022-10-04→ Common Stock (833 underlying)

Footnotes (7)

[F1]Award of Restricted Stock Units under the 2014 Equity Incentive Plan. Vests (x) 25% on June 5, 2016 and (y) 12.5% per six months thereafter.
[F2]The stock option exercise and sale of shares of the Company's common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2015.
[F3]25% of the total number of shares subject to the option vest and become exercisable on 06/06/2014 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter.
[F4]25% of the total number of shares subject to the option vest and become exercisable on 09/24/2013 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter.
[F5]25% of the total number of shares subject to the option vest and become exercisable on 06/04/2015 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter
[F6]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $214.35 to $215.33. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
[F7]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $215.38 to $216.17. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

SYNAGEVA BIOPHARMA CORP

CIK 0000911326

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0000911326

Filing Metadata

Form type: 4
Filed: Jun 8, 8:00 PM ET
Accepted: Jun 9, 6:13 PM ET
Size: 20.8 KB

View on SEC.gov